Trial Profile

An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics, and Tumor Response Profile of the Diacylglycerol Kinase Zeta Inhibitor (DGKzi) BAY 2965501 as Monotherapy, and in Combination, in Participants With Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BAY-2965501 (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Bayer

19 Jun 2025 Status changed from recruiting to active, no longer recruiting.
28 Feb 2025 Planned End Date changed from 10 Aug 2026 to 7 Jun 2027.
28 Feb 2025 Planned primary completion date changed from 10 Aug 2026 to 7 Jun 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com